The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)

被引:0
作者
Zahra Safari
Philippe Gérard
机构
[1] Université Paris-Saclay,Micalis Institute, INRA, UMR1319, Equipe AMIPEM, AgroParisTech
[2] Medical University of Graz,Institute of Pathology
来源
Cellular and Molecular Life Sciences | 2019年 / 76卷
关键词
Gut microbiota; Non-alcoholic fatty liver disease; Germ-free animals; Dysbiosis; Metabolic syndrome; Bile acids; Intestinal permeability; Antibiotics; Probiotics; Prebiotics;
D O I
暂无
中图分类号
学科分类号
摘要
NAFLD is currently the main cause of chronic liver disease in developed countries, and the number of NAFLD patients is growing worldwide. NAFLD often has similar symptoms to other metabolic disorders, including type 2 diabetes and obesity. Recently, the role of the gut microbiota in the pathophysiology of many diseases has been revealed. Regarding NAFLD, experiments using gut microbiota transplants to germ-free animal models showed that fatty liver disease development is determined by gut bacteria. Moreover, the perturbation of the composition of the gut microbiota has been observed in patients suffering from NAFLD. Numerous mechanisms relating the gut microbiome to NAFLD have been proposed, including the dysbiosis-induced dysregulation of gut endothelial barrier function that allows for the translocation of bacterial components and leads to hepatic inflammation. In addition, the various metabolites produced by the gut microbiota may impact the liver and thus modulate NAFLD susceptibility. Therefore, the manipulation of the gut microbiome by probiotics, prebiotics or synbiotics was shown to improve liver phenotype in NAFLD patients as well as in rodent models. Hence, further knowledge about the interactions among dysbiosis, environmental factors, and diet and their impacts on the gut–liver axis can improve the treatment of this life-threatening liver disease and its related disorders.
引用
收藏
页码:1541 / 1558
页数:17
相关论文
共 1240 条
[111]  
Liu YJ(2015)Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids J Zhejiang Univ Sci B 16 436-1319
[112]  
Biswas A(2000)Cross-talk between bile acids and intestinal microbiota in host metabolism and health Gastroenterology 119 1340-458s
[113]  
Hudcovic T(2015)Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis World J Hepatol 7 559-167
[114]  
Tlaskalova-Hogenova H(2014)Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease J Nutr Biochem 25 270-59
[115]  
Kobayashi KS(2015)Influence of dietary fat on intestinal microbes, inflammation, barrier function and metabolic outcomes Future Microbiol 10 889-743
[116]  
Wacklin P(2008)Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease PLoS Biol 6 e280-417
[117]  
Tuimala J(2001)The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing Am J Gastroenterol 96 1251-1285
[118]  
Nikkila J(2008)Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function J Hepatol 48 983-714
[119]  
Sebastian T(2013)Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin Hepatology (Baltimore, MD) 57 2525-1095
[120]  
Makivuokko H(2007)Dietary fructose in nonalcoholic fatty liver disease J Nutr 137 830s-1574